Market Size
The global nanotechnology-enabled drug delivery devices market size was valued at US$ 61.05 billion in 2025 and is forecast to reach US$ 200 billion by 2035, growing at a CAGR of 12.6% during the forecast period 2026-2035.
Nanotechnology-enabled drug delivery devices are advanced systems that use nanotechnology to improve the efficacy, precision, and safety of therapeutic agents. These devices use nanoscale materials like nanoparticles, liposomes, dendrimers, and polymeric micelles to enhance drug solubility, bioavailability, and targeted delivery to specific tissues or cells. These systems minimize side effects, enhance therapeutic outcomes, and enable personalized treatment approaches, particularly in oncology, neurology, and infectious disease treatments.
Key Highlights
- Nanoparticle platforms, including lipid and polymeric systems, generated an estimated 34% of 2025 revenue, equal to USD 20.76 billion.
- Liposomal products represented 27%, or USD 16.48 billion, supported by established oncology, antifungal and other parenteral medicines.
- Oncology accounted for an estimated 36% share and USD 21.98 billion in revenue, making it the largest therapeutic application.
- Injectable products held 58% of the market, equal to USD 35.41 billion, because many nanocarriers require parenteral administration and controlled clinical handling.
- Pharmaceutical and biotechnology companies represented 46% of end-user revenue, or USD 28.08 billion, through commercial products, licensing and development programs.
- North America led with 42% of global revenue, equal to USD 25.64 billion, supported by approved nanomedicines, biotechnology investment and specialized manufacturing.
- Extrahepatic delivery, particle characterization, scalable production and intellectual-property access are the main competitive barriers through 2035.
For more details on this report – Request for Sample
Market Scope
| Metric | Detail |
| 2025 market value | USD 61.05 billion |
| 2035 forecast value | USD 200 billion |
| Forecast CAGR | 12.60% |
| Historical period | 2023–2024 |
| Base year | 2025 |
| Forecast period | 2026–2035 |
| Leading technology | Nanoparticles, including lipid and polymeric particles |
| Leading application | Oncology |
| Leading route | Injectable delivery |
| Largest region | North America |
| Revenue scope | Nano-enabled therapeutics, platform-linked formulations and associated delivery value |
Market Dynamics: Drivers & Restraints
Enhanced Drug Bioavailability and Targeted Delivery
The global market for nanotechnology-enabled drug delivery devices is expanding due to its ability to improve drug bioavailability and targeted delivery. These systems enhance therapeutic effectiveness by delivering drugs to specific tissues or diseased cells, minimizing side effects. They are particularly useful in oncology, neurology, and cardiovascular diseases, as they improve solubility, prolong circulation time, and allow controlled drug release. These innovations also facilitate drug transport across biological barriers, making them crucial for treating complex conditions.
Limited Scalability and Manufacturing Complexities
The global nanotechnology-enabled drug delivery devices market faces significant challenges due to the complexities of large-scale manufacturing, including precise engineering, specialized facilities, and strict quality control measures. Variability in nanoparticle size, stability, and drug-loading efficiency can impact product consistency, leading to regulatory setbacks. High costs associated with maintaining advanced manufacturing infrastructure and ensuring batch-to-batch uniformity further restrict market expansion, limiting the widespread adoption of nanotechnology in drug delivery.
Market Segmentation
By delivery technology
Nanoparticles, including lipid and polymeric systems, led with an estimated 34% share and USD 20.76 billion in 2025 revenue. Lipid nanoparticles are central to mRNA and other nucleic-acid products, while polymeric particles offer controlled-release and material-design flexibility. Their fastest opportunity lies in targeted delivery beyond the liver.
Liposomes accounted for 27%, or USD 16.48 billion. They form the most established nanoscale carrier class across oncology, antifungal and supportive-care products. Nanocrystals represented 16%, equal to USD 9.77 billion, primarily improving the dissolution and bioavailability of poorly soluble compounds.
Micelles held 11%, or USD 6.72 billion, while protein nanoparticles, dendrimers, nanotubes, inorganic particles and other systems generated the remaining 12%, equal to USD 7.33 billion. Several emerging technologies have strong scientific potential but face greater material-characterization and safety requirements.
By therapeutic application
Oncology generated an estimated 36% of 2025 revenue, equal to USD 21.98 billion. The segment includes liposomal chemotherapies, protein nanoparticles, targeted formulations, RNA cancer vaccines and investigational immune-cell delivery. Infectious diseases accounted for 21%, or USD 12.82 billion, supported by vaccines and liposomal anti-infectives.
Anti-inflammatory and immunology applications represented 16%, equal to USD 9.77 billion. Cardiovascular and metabolic diseases held 12%, or USD 7.33 billion, as RNA-silencing and targeted delivery platforms move into lipid and metabolic disorders. Neurology accounted for 10%, equal to USD 6.11 billion, while other applications represented 5%, or USD 3.05 billion.
By route of administration
Injectable delivery dominated with 58% of the market, equal to USD 35.41 billion in 2025. Intravenous, intramuscular, subcutaneous and intratumoral administration enable controlled dosing and are common for biologics, vaccines and oncology formulations.
Oral nanoformulations held 20%, or USD 12.21 billion, primarily through nanocrystals and carriers designed to improve solubility or protect cargo in the gastrointestinal tract. Pulmonary delivery represented 8%, equal to USD 4.88 billion. Topical and transdermal formats accounted for 7%, or USD 4.27 billion, while ocular, nasal and other routes formed the remaining 7%, also USD 4.27 billion.
By end user
Pharmaceutical and biotechnology companies represented an estimated 46% share and USD 28.08 billion in 2025 revenue. This segment includes internal platform development, formulation licensing, clinical products and commercial nanomedicines. Hospitals and clinics accounted for 37%, or USD 22.59 billion, reflecting administration of approved nano-enabled products.
Research institutes and laboratories held 12%, equal to USD 7.33 billion, while contract developers, public programs and other end users represented 5%, or USD 3.05 billion. Contract manufacturing is expected to gain strategic importance as particle characterization and sterile production become more specialized.
Regional and Country-Level Analysis
North America
North America led with an estimated 42% share and USD 25.64 billion in 2025 revenue. The United States generated 36% of the global market, equal to USD 21.98 billion, supported by commercial nanomedicines, RNA-platform companies, specialized manufacturers and deep clinical-development capacity. Canada accounted for 4%, or USD 2.44 billion, with strengths in lipid chemistry, biotechnology research and vaccine development.
The region's opportunity is concentrated in next-generation RNA delivery, oncology combinations and commercial-scale manufacturing. Regulatory expectations for chemistry, manufacturing and controls are high, but a mature investment and licensing environment supports platform transactions.
Europe
Europe represented 27% of 2025 revenue, equal to USD 16.48 billion. Germany held an estimated 5% of the global market, or USD 3.05 billion, supported by mRNA, liposome and pharmaceutical manufacturing capabilities. The United Kingdom and France each represented 4%, equal to USD 2.44 billion. Switzerland, Belgium, the Netherlands and Nordic countries contribute through pharmaceutical headquarters, formulation science and clinical research.
European developers must address medicinal-product regulation, nanomaterial characterization and environmental or worker-safety obligations. Regional funding and cross-border research support early innovation, while fragmented reimbursement creates country-specific launch requirements.
Asia-Pacific
Asia-Pacific accounted for an estimated 24% share and USD 14.65 billion in 2025 revenue. China represented 8% of global revenue, or USD 4.88 billion, supported by expanding biologics, oncology and RNA pipelines. Japan held 6%, equal to USD 3.66 billion, with strengths in liposomal medicines, precision manufacturing and pharmaceutical research. India generated 4%, or USD 2.44 billion, while South Korea represented 3%, equal to USD 1.83 billion.
The region combines high-growth clinical pipelines with cost-competitive manufacturing. Local regulatory requirements, technology-transfer controls and intellectual-property protection influence partnerships. Japan and South Korea offer advanced development capabilities, while China and India provide scale and expanding domestic demand.
Latin America
Latin America represented 4% of global revenue, or USD 2.44 billion, in 2025. Brazil and Mexico are the largest markets through vaccine procurement, oncology treatment and pharmaceutical manufacturing. Access depends on public reimbursement, import pathways and cold-chain infrastructure. Regional manufacturing partnerships can reduce supply risk but require validated technology transfer.
Middle East and Africa
The Middle East and Africa accounted for 3%, equal to USD 1.83 billion, in 2025. Gulf investments in biotechnology and vaccine capacity support selected opportunities, while South Africa contributes clinical and manufacturing expertise. Access to high-cost nano-enabled oncology and genetic medicines remains uneven, making procurement agreements and tiered market strategies important.
Competitive Landscape
Competition spans pharmaceutical companies with marketed nanomedicines, RNA platform developers, specialist delivery companies, lipid suppliers and contract manufacturers. A company's position depends on clinical validation, carrier intellectual property, tissue targeting, formulation analytics and scalable production. Market share cannot be assessed solely by counting patents or preclinical programs because commercial revenue remains concentrated in approved products.
Key Players
Moderna, Inc.; Pfizer Inc.; BioNTech SE; Merck & Co., Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Johnson & Johnson; Novartis AG; Sanofi; GSK; Alnylam Pharmaceuticals; Arrowhead Pharmaceuticals; Arcturus Therapeutics; Bausch Health; Pacira BioSciences; and Mirai Bio.
Detailed Company Profiles
Moderna, Inc.
Moderna develops mRNA medicines whose performance depends on delivery. The company states that it has created numerous proprietary lipid nanoparticles optimized for different cell types and routes, including systemic, intramuscular, intratumoral and pulmonary delivery. Its commercial vaccine experience provides manufacturing and regulatory evidence for large-scale LNP products.
The company is also evaluating inhaled pulmonary delivery and continues to develop oncology and infectious-disease programs. Its competitive strength is the integration of mRNA design, LNP formulation, clinical development and manufacturing. The key strategic challenge is extending delivery beyond established muscle and liver applications while maintaining tolerability for repeated dosing.
Arrowhead Pharmaceuticals
Arrowhead develops RNA-interference medicines using its Targeted RNAi Molecule platform. The platform combines RNA chemistry with targeting structures designed to deliver gene-silencing cargo to selected tissues. Arrowhead describes a pipeline spanning liver, lung, muscle, adipose and central nervous system targets.
Its commercial product REDEMPLO, or plozasiran, is an siRNA therapy designed to suppress apolipoprotein C-III. In May 2026, Arrowhead reported commercial uptake in the United States, regulatory progress in Australia, Europe, China and Canada, and clinical advancement across cardiometabolic programs. The company also signed a worldwide license with Madrigal for ARO-PNPLA3, with USD 25 million upfront and potential development, regulatory and sales milestones of up to USD 975 million.
Jazz Pharmaceuticals
Jazz Pharmaceuticals markets VYXEOS, a liposomal combination of daunorubicin and cytarabine. The formulation maintains a fixed molar ratio of the two active ingredients and is used in specified acute myeloid leukemia settings. VYXEOS demonstrates a central principle of nano-enabled delivery: the carrier can coordinate the pharmacokinetics of multiple drugs rather than only solubilizing one molecule.
Jazz's position is based on an approved oncology product with formulation-specific clinical evidence. The company must maintain complex liposome manufacturing, quality control and hospital access. VYXEOS also provides a commercial benchmark for developers proposing multi-drug nanoparticles or ratio-controlled combination delivery.
Gilead Sciences, Inc.
Gilead's nano-enabled portfolio includes AmBisome, a liposomal formulation of amphotericin B used for serious fungal infections. Liposomal encapsulation changes the distribution and tolerability profile of the active antifungal agent and has created a long-standing commercial product in hospital care.
Gilead benefits from global anti-infective experience, manufacturing oversight and established hospital channels. AmBisome illustrates the durability of validated liposomal products but also highlights access and supply responsibilities in severe infections. The company's position is product-led rather than centered on an external delivery-platform licensing model.
Recent Developments
- On August 6, 2026, the U.S. FDA granted accelerated approval to Replimune's genetically modified oncolytic viral therapy vusolimogene oderparepvec-wtpg with nivolumab for specified advanced melanoma. A viral therapy is not a nanoparticle product, but the approval is relevant to the broader engineered-delivery field because it uses a biological vehicle for localized therapeutic action. It is treated as an adjacent delivery development rather than counted within nanoparticle revenue.
- On July 31, 2026, Moderna's second-quarter update highlighted continued development of its mRNA pipeline, including oncology and respiratory candidates. The programs rely on delivery capabilities spanning LNP formulations and different administration routes, reinforcing the link between pipeline value and carrier performance.
- On May 12–14, 2026, Mirai Bio presented targeted lipid nanoparticle data at the American Society of Gene and Cell Therapy meeting. The company reported CD8-targeted LNP delivery of CAR mRNA in non-human primates, generation of CAR-expressing endogenous T cells and B-cell depletion. It also presented machine-learning-guided optimization of LNP delivery to adipose tissue with reduced off-target liver and spleen delivery.
- On May 7, 2026, Arrowhead reported commercial and regulatory progress for plozasiran and disclosed advancement of its tissue-targeted RNAi pipeline. The update included the first dosing in a clinical study of a dual-functional molecule targeting PCSK9 and APOC3 and human gene-knockdown data from an adipose-directed program.
- On May 5, 2026, Arrowhead announced an exclusive worldwide license with Madrigal Pharmaceuticals for ARO-PNPLA3. The financial structure included a USD 25 million upfront payment and eligibility for milestones of up to USD 975 million, showing the value assigned to targeted RNA delivery assets with clinical data.
- On May 22, 2026, BioNTech outlined progress across its oncology portfolio, including mRNA cancer immunotherapies alongside antibody-drug conjugates and immunomodulators. The update demonstrates how delivery modalities are increasingly combined within multi-platform oncology strategies rather than developed in isolation.
Market Scope
| Metrics | Details | |
| CAGR | 12.6% | |
| Market Size Available for Years | 2025-2035 | |
| Estimation Forecast Period | 2026-2035 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Product Type | Nanocrystals, Nanoparticles, Liposomes, Micelles, Nanotubes, Others |
| Application | Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective, Others | |
| End-User | Hospitals and Clinics, Research Institutes and Laboratories, Pharmaceutical and Biotechnology Companies, Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global nanotechnology-enabled drug delivery devices market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Target Audience
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
